Search clinical trials for: Immunotherapeutic GSK2132231A

Total 23 results

GlaxoSmithKline

Completed

Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

Melanoma

France, Belgium
GlaxoSmithKline

Completed

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma (PREDICT)

Melanoma

United States, Spain, Germany, France, Poland, Italy, Ireland, Russian Federation
GlaxoSmithKline

Terminated

A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients

Melanoma

Belgium, France
McGill University Health Centre/Research Institute...
Université de Montréal; Argos Therapeutics

Completed

A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.

Acquired Immunodeficiency Syndrome | HIV Seropositivity

Canada
Argos Therapeutics

Completed

Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

Renal Cell Carcinoma

Canada, United States
GlaxoSmithKline

Terminated

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell

United States, Australia, Canada, Netherlands, Finland, Taiwan, Czechia, Estonia, Spain, Argentina, Belgium, France, Sweden, Germany, Israel, Italy, Korea, Republic of, Singapore, Ukraine, United Kingdom, Austria, Ireland, Thailand, C... and more
Jules Bordet Institute

Unknown

Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia (ASCI)

Effects of Immunotherapy | Acute Myelogenous Leukemia | Myeloid Leukemia in Remission

Belgium
GlaxoSmithKline

Completed

Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Melanoma

France, Italy, Germany, Netherlands, Switzerland, United Kingdom, Austria, Australia
Ludwig Institute for Cancer Research
Memorial Sloan Kettering Cancer Center; Fox Chase Cancer Center; GlaxoSmithKline and other collaborators

Completed

MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Multiple Myeloma

United States
GlaxoSmithKline

Completed

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Melanoma

Germany, Czechia, France, Italy, Russian Federation, Poland
GlaxoSmithKline

Completed

A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer

Neoplasms, Breast

Belgium, United States, Australia, France, Italy
Duke University
Immunotope

Completed

Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease

Breast Cancer

United States
GlaxoSmithKline

Terminated

Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery

Lung Cancer, Non-Small Cell

United States, France, Germany, Russian Federation, Poland, Italy
GlaxoSmithKline

Terminated

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

Melanoma

Norway, Argentina, Greece
GlaxoSmithKline

Completed

Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy

Leukaemia, Myelocytic, Acute

Germany, France, United States
GlaxoSmithKline

Completed

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)

Leukaemia, Myelocytic, Acute

United States, France
Cliniques universitaires Saint-Luc- Université...

Active, not recruiting

Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy (Plasma-Target)

Cancer

Belgium
Institut Bergonié
French Sarcoma Group

Recruiting

National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group (BCB-Sarcomes)

Sarcoma

France
Gary Onik MD

Completed

A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. (NIRPA)

Adenocarcinoma

United States
GlaxoSmithKline

Terminated

Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

Lung Cancer, Non-Small Cell

Canada, Italy, Belgium, France, Germany, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Cryoablation for the Treatment of Metastatic Cancer

Metastatic Malignant Neoplasm

United States
Zhejiang Cancer Hospital

Not yet recruiting

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Non-small Cell Lung Cancer Stage III
GlaxoSmithKline

Terminated

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer (INDUCT)

Neoplasms, Breast

United States, Belgium, United Kingdom, Germany, Russian Federation, Italy, France

3

Subscribe